NASDAQ:PYXS - Pyxis Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 55.76 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$12.84
▲ +0.2 (1.58%)

This chart shows the closing price for PYXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pyxis Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PYXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PYXS

Analyst Price Target is $20.00
▲ +55.76% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pyxis Oncology in the last 3 months. The average price target is $20.00, with a high forecast of $25.00 and a low forecast of $16.00. The average price target represents a 55.76% upside from the last price of $12.84.

This chart shows the closing price for PYXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Pyxis Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2021Lifesci CapitalReiterated RatingOutperformLow
11/2/2021William BlairReiterated RatingBuyLow
11/2/2021Jefferies Financial GroupInitiated CoverageBuy$25.00Low
11/2/2021Bank of AmericaInitiated CoverageNeutral$16.00Low
11/2/2021Credit Suisse GroupInitiated CoverageOutperform$19.00Low
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pyxis Oncology logo
Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.
Read More

Today's Range

Now: $12.84
Low: $12.13
High: $13.29

50 Day Range

MA: N/A

52 Week Range

Now: $12.84
Low: $10.25
High: $19.00

Volume

83,505 shs

Average Volume

213,170 shs

Market Capitalization

$420.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pyxis Oncology?

The following sell-side analysts have issued reports on Pyxis Oncology in the last year: Bank of America Co., Credit Suisse Group AG, Jefferies Financial Group Inc., Lifesci Capital, and William Blair.
View the latest analyst ratings for PYXS.

What is the current price target for Pyxis Oncology?

3 Wall Street analysts have set twelve-month price targets for Pyxis Oncology in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 55.8%. Jefferies Financial Group Inc. has the highest price target set, predicting PYXS will reach $25.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $16.00 for Pyxis Oncology in the next year.
View the latest price targets for PYXS.

What is the current consensus analyst rating for Pyxis Oncology?

Pyxis Oncology currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PYXS will outperform the market and that investors should add to their positions of Pyxis Oncology.
View the latest ratings for PYXS.